|Bid||29.00 x 900|
|Ask||32.27 x 800|
|Day's Range||31.06 - 31.06|
|52 Week Range||13.25 - 48.29|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for RGC
Every investor in Regencell Bioscience Holdings Limited ( NASDAQ:RGC ) should be aware of the most powerful shareholder...
HONG KONG, September 12, 2022--Regencell Bioscience Holdings Limited (Nasdaq: RGC) ("Regencell") today announced its interim results from its second efficacy trial.
By Beth Senko, CFA NASDAQ:RGC Investors have faced challenging and volatile markets so far in 2022 as they sort through issues of inflation, supply chain disruption, continued covid issues, rising interest rates, and the disruption of the war in Ukraine. The S&P 500 has come close to bear market levels, down 19% in mid-June. Times of turbulence affect all stocks, large and small. It can be